BREAKING: Helus Pharma (HELP) says its Phase 3 APPROACH trial of HLP003, an adjunctive treatment for major depressive disorder, met its primary endpoint — a 7.6-point placebo-adjusted improvement on the MADRS depression scale at Week 6 (p<0.0001), holding at 7.0 points at Week 12, in 222 patients. The company also reported a wider fiscal Q2 net loss of $103.1M (vs $33.7M a year ago) with $171.1M in cash. Shares swung wildly on the news. #Helus #HELP #Biotech #Stocks #ClinicalTrial
193 Views